McNicoll, Lewis & Vlak Reiterates Vivus Buy, $16 PT

McNicoll, Lewis & Vlak reiterated its Vivus

Buy rating and $16 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, " Today, VVUS announced data from the 47th European Association for the Study of Diabetes (EASD), which highlighted the long-term benefits of Qnexa treatment in metabolically-impaired patients with pre-diabetes, diabetes, and metabolic syndrome." Shares of Vivus were trading at $8.81 at the time of posting, down 0.79% from Thursday's market close.